
© 2025 Der Aktionär
Realtime | Geld | Brief | Zeit |
---|---|---|---|
136,66 | 136,80 | 17:04 | |
136,60 | 136,82 | 17:04 |
Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
15:54 | Johnson & Johnson Reports Positive Phase 3 ASTRO Study Data For TREMFYA In Ulcerative Colitis | NEW BRUNSWICK (dpa-AFX) - Drug major Johnson & Johnson (JNJ) announced Monday positive new data from the Phase 3 ASTRO study evaluating TREMFYA (guselkumab) subcutaneous (SC) induction therapy... ► Artikel lesen | |
15:30 | Teva, Alvotech get FDA nod for Johnson & Johnson biosimilar | ||
15:06 | J&J Reports Positive Data From Long-term Extension Study Of TREMFYA In Ulcerative Colitis | NEW BRUNSWICK (dpa-AFX) - Johnson & Johnson (JNJ) Monday reported positive data from Phase 3 QUASAR long-term extension study of TREMFYA in adults with moderately-to-severely active ulcerative... ► Artikel lesen | |
10:00 | Nanobiotix Reveals Favorable Results Of JNJ-1900 Study Pancreatic Cancer; Seeks Further Evaluation | NEW BRUNSWICK (dpa-AFX) - Nanobiotix S.A. (NBTX), a biotechnology company focused on nanoparticle-based cancer treatments, announced Monday positive full results from the completed dose escalation... ► Artikel lesen | |
08:06 | Nanobiotix S.A.: Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer | Results demonstrated favorable safety, injection feasibility, and encouraging oncologic outcomes in patients (n=22) with locally advanced or borderline resectable pancreatic cancerMedian Overall Survival... ► Artikel lesen |